Innovation Days
About
Research
Products
Investors
Careers
Agenda
fr
Press Releases
Our latest news and press releases
All
2022
2021
2020
2019
2018
2017
05
May
2022
16:00 E.S.T.
Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results
Read more
28
Apr
2022
08:00 E.S.T.
Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
Read more
27
Apr
2022
04:00 E.S.T.
Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
Read more
08
Apr
2022
16:30 E.S.T.
Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Read more
11
Mar
2022
13:15 E.S.T.
Cellectis to Participate in Two Upcoming Investor Conferences in March
Read more
03
Mar
2022
13:46 E.S.T.
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results
Read more
24
Feb
2022
13:13 E.S.T.
Cellectis to Hold Fourth Quarter 2021 Earnings Call on Friday March 4, 2022 at 8:00AM EST
Read more
18
Feb
2022
15:22 E.S.T.
Calyxt Announces Pricing of Offering of Common Stock and Warrants and Updates Business and Risk Factor Disclosure
Read more
10
Feb
2022
16:44 E.S.T.
Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer
Read more
10
Jan
2022
16:30 E.S.T.
Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials
Read more
Prev
1
2
3
4
Next